Patients with a known genetic predisposition to breast cancer p53基因病理突变(利-弗劳梅尼综合征)(2B类)(参见NCCN遗传/家族高风险评定指南:乳腺癌、卵巢癌和胰腺癌) Pathologic p53 mutation (Li-Fraumeni syndrome) (category 2B) (See NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast, Ova...
Patients with a known genetic predisposition to breast cancer p53基因病理突变(利-弗劳梅尼综合征)(2B类)(参见NCCN遗传/家族高风险评定指南:乳腺癌、卵巢癌和胰腺癌) Pathologic p53 mutation (Li-Fraumeni syndrome) (category 2B) (See NCCN Guidelines for Genetic/F...
[2]NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Non Small Cell Lung Cancer. Version 2.2024. [3]Paul DiSilvestro , et al. Overall survival (OS) at 7-year (y) follow-up (f/u) in patients (pts) with n...
Clinical indications and applications, bullet 5 revised:The utility of MRI in follow-up screening of most patients with prior breast cancer is undefined and annual MRI is recommended in patients with personal history of breast cancer who: 1) were diagnosed age <50 or 2) have dense breasts.It ...
[2]NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Non Small Cell Lung Cancer. Version 2.2024. [3]Paul DiSilvestro , et al. Overall survival (OS) at 7-year (y) follow-up (f/u) in patients (pts) with newly diagnosed advanced ovarian cancer (OC) and a BRCA mutation ...
Our corporate supporters do not participate in the development of the NCCN Guidelines for Patients and are not responsible for the content and recommendations contained therein. Additional support is provided by Ovarian Cancer Research Alliance is committed to curing ovarian cancer, advocating for ...
1FlemingGF,SeidmanJ,YemelyanovaA,andLengylE:EpithelialOvarianCancer.InChiDS,BerchuckA,DizonD,etal.(eds):PrinciplesandPracticeofGynecologicOncology,7thed,Philadelphia,LippincottWilliamsWilkins,2017:611-705.OV-A第1页,共4页NCCNGuidelinesVersion1.2023卵巢癌/输卵管癌/原发性腹膜癌NCCN指南索引目录讨论...
Reference 2 added: Turner NC, Oliveira M, Howell SJ, et al. Capivasertib in hormone receptor-positive advanced breast cancer. N Engl J Med. 2023;388(22):2058-2070. 原文共享 相关链接 循环肿瘤基因指导晚期乳腺癌靶向治疗 新英格兰:乳腺癌内分泌治疗耐药有救 ...
Reference 2 added: Turner NC, Oliveira M, Howell SJ, et al. Capivasertib in hormone receptor-positive advanced breast cancer. N Engl J Med. 2023;388(22):2058-2070. 原文共享 相关链接 晚期三阴性乳腺癌患者一线治疗新方案 晚期乳腺癌芳香酶抑制剂耐药后新方案 ...
NCCN肿瘤学临床实践指南(NCCN指南®) 卵巢癌 (包括输卵管癌和原发性腹膜癌) 2022.v1—2022年01月18日 NCCN.org NCCN患者指南®,网址:/patients 继续 ® ® ® Version 1.2022,01/08/22© 2022 National Comprehensive Cancer Network (NCCN ),All rights reserved. NCCN Guidelines andthis ...